RefractoryRenalDialysis PatientsSpuriousHyperkalemiaPatientsExcretionSevereOccurClinical TrialsConcentrationsTreatmentDiseasesKidneyPlasmaHyperviscosity syndromeHypercalcemiaNewly diagnosedSerumDialysisPatientsHypocalcemiaMonoclonalParaproteinemiaDysfunctionPhosphate administrationClinical trialIntracellularOccasionallyTherapyTOPICIntact
Refractory9
- Study of bortezomib administered in combination with vorinostat or placebo in patients with relapsed or refractory multiple myeloma. (novoclinica.com)
- Two Phase I dose-ranging studies of a regimen combining vorinostat and bortezomib among patients with relapsed as well as end-stage, refractory multiple myeloma have been conducted. (novoclinica.com)
- In addition to colorectal cancer, perifosine is currently in a Phase 3 trial, under SPA, for the treatment of relapsed/refractory multiple myeloma, with Orphan Drug Status and Fast Track designation granted. (traderpower.com)
- Multiple myeloma in patients whose disease has relapsed or is refractory despite receiving ≥1 previous drug therapies (as monotherapy). (unboundmedicine.com)
- Multiple myeloma in patients whose disease has relapsed or is refractory despite receiving 1-3 previous drug therapies (in combination with dexamethasone, or lenalidomide + dexamethasone, or daratumumab + dexamethasone, or daratumumab/hyaluronidase + dexamethasone, or isatuximab + dexamethasone). (unboundmedicine.com)
- Background aims: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). However, CAR-T-related tumor lysis syndrome (TLS) has been observed. (bvsalud.org)
- OBJECTIVE: To investigate the risk factors of tumor lysis syndrome (TLS) in relapsed/refractory multiple myeloma (MM) patients undergoing B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. (bvsalud.org)
- The parties entered an international strategic deal in December 2022 to jointly develop and market a CART-ddBCMA candidate for relapsed or refractory multiple myeloma. (pharmaceutical-technology.com)
- Findings from the Phase 3 COLUMBA study will be presented ( Abstract #8005 ) evaluating the subcutaneous formulation in the treatment of patients with relapsed or refractory multiple myeloma. (jnj.com)
Renal3
- Hyperphosphatemia occasionally results from a transcellular shift of phosphate into the extracellular space that is so large that the renal excretory capacity is overwhelmed. (msdmanuals.com)
- Calcium phosphate precipitation in the renal tubules may also contribute to acute kidney injury in patients with severe hyperphosphatemia from the tumor lysis syndrome, especially if the urine is alkaline. (nejm.org)
- Hyperphosphatemia and deposition of calcium phosphate crystals in the renal tubules can also lead to AKI. (your-doctor.net)
Dialysis Patients2
- Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders. (medscape.com)
- Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. (medscape.com)
Spurious1
- Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. (medscape.com)
Hyperkalemia2
- TLS is associated with number of metabolic changes such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. (bvsalud.org)
- Among the consequences of hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia is the inhibition of 5' AMP-activated protein kinase (AMPK). (bvsalud.org)
Patients7
- Although most patients with hyperphosphatemia are asymptomatic, they occasionally report hypocalcemic symptoms, such as muscle cramps, tetany, and perioral numbness or tingling. (medscape.com)
- More commonly, patients report symptoms related to the underlying cause of the hyperphosphatemia. (medscape.com)
- Bortezomib is indicated for the treatment of patients with multiple myeloma. (novoclinica.com)
- In patients multiple myeloma, the globulin concentration is often increased, leading to excessive binding of calcium to the monoclonal paraprotein and occasional elevation of the total serum calcium concentration, yet the ionized calcium level may be normal in these individuals. (medscape.com)
- Q. What are some of the causes of acute kidney injury in patients with multiple myeloma? (nejm.org)
- A. Acute kidney injury complicates multiple myeloma in, depending on the definition used, 20 to 50% of patients. (nejm.org)
- Kite executive vice-president Cindy Perettie stated: "We are pleased to see the momentum with the CART-ddBCMA multiple myeloma programme, enabling Kite to enter an area of high unmet need and bring a new, potentially best-in-class cell therapy to patients. (pharmaceutical-technology.com)
Excretion2
- Hyperphosphatemia-that is, abnormally high serum phosphate levels-can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. (medscape.com)
- Nephrocalcinosis is connected with conditions that cause hypercalcaemia, hyperphosphatemia, and the increased excretion of calcium, phosphate, and/or oxalate in the urine. (wikipedia.org)
Severe1
- However, even severe hyperphosphatemia is for the most part clinically asymptomatic. (medscape.com)
Occur2
- Hyperphosphatemia can also occur with excessive oral phosphate administration and occasionally with overzealous use of enemas containing phosphate. (msdmanuals.com)
- Severely elevated phosphate levels (hyperphosphatemia) may also occur. (cancerhealth.com)
Clinical Trials1
- Mycophenolate has demonstrated remarkable effectiveness in multiple clinical trials and real-world settings. (1mgstore.com)
Concentrations2
- Steady-state concentrations of both venlafaxine and ODV in plasma were attained within 3 days of multiple-dose therapy. (drugs.com)
- Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. (medscape.com)
Treatment1
- As we continue to advance our portfolio and pipeline, we are pleased to present important new findings for ERLEADA in metastatic castration-sensitive prostate cancer, and for DARZALEX in the treatment of newly diagnosed multiple myeloma and as a subcutaneous formulation," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. (jnj.com)
Diseases1
- Large kidneys are associated with diseases such as early diabetic nephropathy, multiple myeloma, polycystic kidney disease, and human immunodeficiency virus (HIV)-associated glomerulonephritis. (medscape.com)
Kidney1
- It is caused by multiple different conditions and is determined by progressive kidney dysfunction. (wikipedia.org)
Plasma2
- Plasma clearance, elimination half-life and steady-state volume of distribution were unaltered for both venlafaxine and ODV after multiple-dosing. (drugs.com)
- Множинна мієлома Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (msdmanuals.com)
Hyperviscosity syndrome2
- In addition, hypercalcemia associated with osteolysis by myeloma cells, deposition of amyloid in glomeruli, hyperviscosity syndrome, hyperphosphatemia, renal infiltration of myeloma cells are also the causes of renal dysfunction. (vegfr-3inhibitor.com)
- Hyperviscosity Syndrome a. from Multiple Myeloma b. from Polycythemia Vera c. from Chronic Myelogenous Leukemia d. from acute leukemias e. from Waldenstrom's Macoglobulinemia 4. (tomwademd.net)
Hypercalcemia3
- Determining whether renal failure is primary or secondary to hypercalcemia caused by another disorder when hyperphosphatemia and hypercalcemia coexist with azotemia can be difficult. (vin.com)
- Usually Sapanisertib molecular weight when any symptom such as bone symptoms, renal dysfunction, anemia, or hypercalcemia is observed, it is diagnosed as symptomatic multiple myeloma and treatment should be started. (vegfr-3inhibitor.com)
- When hyperviscosity is present you need to check for hypercalcemia, hyperphosphatemia, and hyperkalemia. (tomwademd.net)
Newly diagnosed2
- 15 % of newly diagnosed multiple myeloma patients have complication of renal dysfunction and the rate increases as the disease progresses. (vegfr-3inhibitor.com)
- Although these are the data before introduction of novel agents, in the 423 patients with newly diagnosed multiple myeloma, patients with renal dysfunction (22 %) showed significantly shorter survival time compared to the patients with normal renal function (8.6 vs. 34.5 months). (vegfr-3inhibitor.com)
Serum3
- Hyperphosphatemia-that is, abnormally high serum phosphate levels-can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. (medscape.com)
- multiple fractures and prolonged immobilization, which release bone calcium and increase the serum calcium level. (family-health-information.com)
- Increased serum viscosity usually results from increased circulating serum immunoglobulins and can be seen in such diseases as Waldenström macroglobulinemia and multiple myeloma. (tomwademd.net)
Dialysis2
- Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders. (medscape.com)
- Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. (medscape.com)
Patients8
- Although most patients with hyperphosphatemia are asymptomatic, they occasionally report hypocalcemic symptoms, such as muscle cramps, tetany, and perioral numbness or tingling. (medscape.com)
- More commonly, patients report symptoms related to the underlying cause of the hyperphosphatemia. (medscape.com)
- In 197 patients diagnosed as multiple myeloma during 12 years (1995-2006) in our facility, 3.6 % of IgG type and 8.9 % of IgA type showed higher than 2 mg/dL of creatinine on the first visit, were whereas BJP type accounted for 36.8 % (Fig. 8). (vegfr-3inhibitor.com)
- Chronic prerenal disease occurs in patients with chronic heart failure or cirrhosis with persistently decreased renal perfusion, which increases the propensity for multiple episodes of an intrinsic kidney injury, such as acute tubular necrosis (ATN). (nih.gov)
- FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. (nih.gov)
- Multiple myeloma in patients whose disease has relapsed or is refractory despite receiving ≥1 previous drug therapies (as monotherapy). (drugguide.com)
- Multiple myeloma in patients whose disease has relapsed or is refractory despite receiving 1-3 previous drug therapies (in combination with dexamethasone, or lenalidomide + dexamethasone, or daratumumab + dexamethasone, or daratumumab/hyaluronidase + dexamethasone, or isatuximab + dexamethasone). (drugguide.com)
- MEN type 1 and MEN type 2A: Patients with multiple gland hyperplasia in the absence of renal disease should be screened for MEN-I gene mutation. (unboundmedicine.com)
Hypocalcemia1
- Secondary HPT: appropriate increased secretion of PTH in response to potential hypocalcemia and/or hyperphosphatemia. (unboundmedicine.com)
Monoclonal1
- Multiple Myeloma Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (msdmanuals.com)
Paraproteinemia1
- Multiple myeloma or other paraproteinemia. (renalandurologynews.com)
Dysfunction3
- It is caused by multiple different conditions and is determined by progressive kidney dysfunction. (wikipedia.org)
- Bence Jones protein (BJP) type and IgD type of myeloma that excrete high amount of Bence Jones protein into urine show high frequency of renal dysfunction. (vegfr-3inhibitor.com)
- Therefore, although renal dysfunction in multiple myeloma is a poor prognostic factor, good prognosis can be expected if the treatment restores renal function. (vegfr-3inhibitor.com)
Phosphate administration1
- Hyperphosphatemia can also occur with excessive oral phosphate administration and occasionally with overzealous use of enemas containing phosphate. (msdmanuals.com)
Clinical trial1
- Contact: There may be multiple sites in this clinical trial. (novoclinica.com)
Intracellular1
- Hyperphosphatemia results from the rapid release of intracellular phosphorus. (oncolink.org)
Occasionally1
- Hyperphosphatemia occasionally results from a transcellular shift of phosphate into the extracellular space that is so large that the renal excretory capacity is overwhelmed. (msdmanuals.com)
Therapy1
- Steady-state concentrations of both venlafaxine and ODV in plasma were attained within 3 days of multiple-dose therapy. (nih.gov)
TOPIC1
- Access free multiple choice questions on this topic. (nih.gov)
Intact1
- Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. (medscape.com)